Stock Track | Veracyte Soars 17.77% Intraday on Strong Q1 Earnings Beat, Raised Guidance and Analyst Upgrades

Stock Track05-06

Veracyte's stock soared 17.77% during intraday trading on Wednesday, marking a significant upward movement for the diagnostic company.

The surge follows the release of Veracyte's first-quarter 2026 financial results, which significantly exceeded analyst expectations. The company reported quarterly earnings of $0.52 per share, beating consensus estimates, while revenue reached $139.1 million, representing a 21% year-over-year increase. Investor sentiment was further bolstered by Veracyte's upward revision of its full-year 2026 revenue guidance to a range of $582 million to $592 million.

The positive earnings report was complemented by bullish analyst actions, including price target increases from Leerink Partners and UBS, as well as maintained Buy ratings from multiple firms. These developments collectively drove strong investor confidence in Veracyte's growth trajectory.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1155955988?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 23:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155955988","market":"nz","top_or_hot":-1,"title":"Stock Track | Veracyte Soars 17.77% Intraday on Strong Q1 Earnings Beat, Raised Guidance and Analyst Upgrades","media":"Stock Track","content":"<p>Veracyte's stock soared 17.77% during intraday trading on Wednesday, marking a significant upward movement for the diagnostic company.</p><p>The surge follows the release of Veracyte's first-quarter 2026 financial results, which significantly exceeded analyst expectations. The company reported quarterly earnings of $0.52 per share, beating consensus estimates, while revenue reached $139.1 million, representing a 21% year-over-year increase. Investor sentiment was further bolstered by Veracyte's upward revision of its full-year 2026 revenue guidance to a range of $582 million to $592 million.</p><p>The positive earnings report was complemented by bullish analyst actions, including price target increases from Leerink Partners and UBS, as well as maintained Buy ratings from multiple firms. These developments collectively drove strong investor confidence in Veracyte's growth trajectory.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Veracyte Soars 17.77% Intraday on Strong Q1 Earnings Beat, Raised Guidance and Analyst Upgrades</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Veracyte Soars 17.77% Intraday on Strong Q1 Earnings Beat, Raised Guidance and Analyst Upgrades\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-06 23:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Veracyte's stock soared 17.77% during intraday trading on Wednesday, marking a significant upward movement for the diagnostic company.</p><p>The surge follows the release of Veracyte's first-quarter 2026 financial results, which significantly exceeded analyst expectations. The company reported quarterly earnings of $0.52 per share, beating consensus estimates, while revenue reached $139.1 million, representing a 21% year-over-year increase. Investor sentiment was further bolstered by Veracyte's upward revision of its full-year 2026 revenue guidance to a range of $582 million to $592 million.</p><p>The positive earnings report was complemented by bullish analyst actions, including price target increases from Leerink Partners and UBS, as well as maintained Buy ratings from multiple firms. These developments collectively drove strong investor confidence in Veracyte's growth trajectory.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VCYT","symbol_name":"Veracyte Inc","start_time":0,"source_url":"","article_id":"1155955988","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155955988","pubTimestamp":1778079731,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Veracyte's stock soared 17.77% during intraday trading on Wednesday, marking a significant upward movement for the diagnostic company.The surge follows the release of Veracyte's first-quarter 2026...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VCYT":"Veracyte Inc"},"translate_title":"个股追踪|Veracyte盘中飙升17.77%，因Q1盈利强劲、指引上调和分析师升级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VCYT":1},"content_text":"Veracyte's stock soared 17.77% during intraday trading on Wednesday, marking a significant upward movement for the diagnostic company.The surge follows the release of Veracyte's first-quarter 2026 financial results, which significantly exceeded analyst expectations. The company reported quarterly earnings of $0.52 per share, beating consensus estimates, while revenue reached $139.1 million, representing a 21% year-over-year increase. Investor sentiment was further bolstered by Veracyte's upward revision of its full-year 2026 revenue guidance to a range of $582 million to $592 million.The positive earnings report was complemented by bullish analyst actions, including price target increases from Leerink Partners and UBS, as well as maintained Buy ratings from multiple firms. These developments collectively drove strong investor confidence in Veracyte's growth trajectory.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1155955988","isCrawlerRequest":true}